论文部分内容阅读
目的:探讨β受体阻滞剂倍他乐克在充血性心力衰竭中的应用。方法:选择充血性心力衰竭患者68例,随机分成两组。对照组予传统治疗,治疗组在传统治疗的基础上加用倍他乐克治疗4周后,比较治疗后两组患者临床指标变化,评估其临床有效性和安全性。结果:倍他乐克对充血性心力衰竭患者的心功能可明显改善,4周有效率83.8%。结论:在常规抗心力衰竭药物治疗基础上加用β受体阻滞剂可明显改善患者心脏功能,提高患者生存率。
Objective: To investigate the application of β-blocker betametabol in congestive heart failure. Methods: Sixty-eight patients with congestive heart failure were randomly divided into two groups. The patients in the control group were treated with traditional treatment. The patients in the treatment group were treated with metoprolol for 4 weeks on the basis of the traditional treatment. The changes of clinical indexes in the two groups were compared to evaluate the clinical efficacy and safety. Results: Betaloc can significantly improve cardiac function in patients with congestive heart failure, with an effective rate of 83.8% at 4 weeks. Conclusion: Adding beta-blockers to conventional anti-heart failure drug therapy can significantly improve cardiac function and improve patient survival.